報價延遲最少15分鐘:2024/12/23 22:24 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.96 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.79/-1.94
|
|
企業價值
306.41M
|
| 資產負債 |
|
每股賬面淨值
5.35
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:24 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. |